Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs

British Journal of Rheumatology
R H StraubB Lang

Abstract

The aim of this study was to determine prognostic markers for the outcome after 36 months of therapy with disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) and to study serial cytokine serum levels. During 36 months, 20 patients receiving DMARDs (nine patients gold sodium thiomalate and 11 patients methotrexate, no comparison undertaken) were followed for clinical and laboratory data. Investigation at baseline, 12, 24 and 36 months, included clinical, radiological and laboratory parameters such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and interleukin (IL)-1 beta, IL-6, tumor necrosis factor alpha (TNF-alpha), IL-1 receptor antagonist (IL-1RA) and IL-2. During the 3 yr of therapy, the patients showed significant clinical improvement and decline of ESR, CRP, and serum levels of IL-6 and IL-2. The decrease in IL-6 serum levels during the first year of therapy correlated significantly with the decrease, after 36 months, in the number of inflamed joints (r = 0.7608, P < 0.005), Lansbury index (r = 0.6642, P < 0.005) and morning stiffness (r = -0.6561, P < 0.005). In contrast to IL-6 or IL-2, TNF-alpha and IL-1RA did not vary significantly during the 3 yr of therap...Continue Reading

Citations

Sep 7, 1999·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·S A Brod
Jul 17, 2001·Annals of the Rheumatic Diseases·M CutoloR H Straub
Feb 14, 2014·BioMed Research International·Yuji Yoshida, Toshio Tanaka
Nov 21, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sohita Dhillon
Jul 5, 2005·Expert Opinion on Investigational Drugs·K J KallenS Rose-John
Aug 2, 2012·Expert Opinion on Biological Therapy·Zoe Ash, Paul Emery
Sep 1, 2009·Expert Opinion on Investigational Drugs·Robert J MootsJohn D Isaacs
May 7, 2010·Joint, Bone, Spine : Revue Du Rhumatisme·Benoit Le GoffYves Maugars
Nov 8, 2015·Cytokine·Keyla Santos Guedes de SáAntonio Carlos Rosário Vallinoto
May 14, 2011·Arthritis and Rheumatism·Inge R Klein-WieringaAndreea Ioan-Facsinay
Jan 26, 2010·Journal of Clinical Pharmacology·Nicolas FreyThasia Woodworth
Jun 1, 2015·Rheumatology and Therapy·Andra F Negoescu, Andrew J K Östör
Feb 1, 2009·Reumatología clinica·José Luis Pablos Álvarez
Jul 7, 2010·The Korean journal of laboratory medicine·So Young KangWoo In Lee
Nov 30, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ali Berkant AvciGerd Rüdiger Burmester
Feb 5, 2021·Pharmacogenomics and Personalized Medicine·Renata SokolikKatarzyna Bogunia-Kubik
Apr 22, 2021·Cellular and Molecular Life Sciences : CMLS·Jian LuShengjun Wang
Nov 8, 2002·Biochimica Et Biophysica Acta·Karl-Josef Kallen
Dec 27, 2019·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Ronald Man Lung Yip, Cheuk Wan Yim

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.